The COUNTER-COVID study: Oral imatinib to reverse pulmonary vascular leak and disease burden in COVID-19

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.043E+13

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $546,881.64
  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principle Investigator

    Pending
  • Research Location

    Netherlands, Europe
  • Lead Research Institution

    Amsterdam University Medical Center - location VUmcǨǨ Ǩ
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Project description One in five patients with COVID-19 develops serious lung damage, necessitating hospitalization or even an Intensive Care Unit. This lung damage is caused, among other things, by leakage in the smallest blood vessels of the lung, whereby fluid escapes from the bloodstream and fills the alveoli. The fluid in the alveoli seriously impedes oxygen uptake and causes life-threatening oxygen deficiency. There are currently no medications to prevent leakage of small blood vessels. Research and expected outcomes Previous research in the laboratory has shown that the existing drug imatinib prevents blood vessel leakage. This protective effect of imatinib on the blood vessel wall can therefore potentially be used in patients with COVID-19. The COUNTER-COVID study tests whether patients treated with imatinib recover faster than patients who receive standard care.